Related references
Note: Only part of the references are listed.Potential drug interactions in cancer patients receiving supportive care exclusively
Rachel P. Riechelmann et al.
JOURNAL OF PAIN AND SYMPTOM MANAGEMENT (2008)
Symptom and medication profiles among cancer patients attending a palliative care clinic
Rachel P. Riechelmann et al.
SUPPORTIVE CARE IN CANCER (2007)
Potential drug interactions and duplicate prescriptions among cancer patients
Rachel P. Riechelmann et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Polypharmacy in older oncology patients and the need for an interdisciplinary approach to side-effect management
K. C. Sokol et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2007)
The pharmacological importance of cytochrome CYP3A4 in the palliation of symptoms: review and recommendations for avoiding adverse drug interactions
Abdo Haddad et al.
SUPPORTIVE CARE IN CANCER (2007)
Drug interactions in cancer therapy
Charity D. Scripture et al.
NATURE REVIEWS CANCER (2006)
Potential for drug interactions in hospitalized cancer patients
RP Riechelmann et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2005)
Significant effect of capecitabine on the pharmacokinetics and pharmacodynamics of warfarin in patients with cancer
R Camidge et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Paracetamol:: a haemorrhagic risk factor in patients on warfarin
I Mahé et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2005)
Classification and occurrence of clinically significant drug interactions with irinotecan and oxaliplatin in patients with metastatic colorectal cancer
FGA Jansman et al.
CLINICAL THERAPEUTICS (2005)
Absolute contraindications in relation to potential drug interactions in outpatient prescriptions:: analysis of the first five million prescriptions in 1999
L Guédon-Moreau et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Dosing practices and risk factors for bleeding in patients receiving enoxaparin for the treatment of an acute coronary syndrome
C Macie et al.
CHEST (2004)
Combined use of SSRIs and NSAIDs increases the risk of gastrointestinal adverse effects
JCF de Jong et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Interaction between paclitaxel and warfarin
ME Thompson et al.
ANNALS OF ONCOLOGY (2003)
Fatal adverse drug events: the paradox of drug treatment
I Buajordet et al.
JOURNAL OF INTERNAL MEDICINE (2001)
Proton pump inhibitors and their drug interactions: an evidence-based approach
LB Gerson et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2001)
Potentiation of vitamin K antagonists by high-dose intravenous methylprednisolone
N Costedoat-Chalumeau et al.
ANNALS OF INTERNAL MEDICINE (2000)
Share Paper
